FDA recall record

SHOPPERS- PLAZA FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and recall — FDA D-0207-2025

Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide

Class Iclassification
D-0207-2025official record ID
Jan 29, 2025report date

Recall record at a glance

Official recordD-0207-2025
CategoryDrug Recalls
ClassificationClass I
FDA record statusOngoing
Recalling firmSHOPPERS- PLAZA
Report dateJan 29, 2025
Recall initiation dateDec 16, 2024
Quantity172 180-count bottles
LocationHawthorne, CA, United States

Official product description

FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by Shoppers-Plaza, Hawthorne, CA 90250. Product of India. UPC 8 26656 69047 7

Why the product was recalled

Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide

Distribution information

Nationwide via internet sales

How to read the classification

FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Press Release.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.